Bumper crop of new drugs fails to lift big pharma R&D returns
Projected returns at 12 top drugmakers falls to an 8-year low of only 3.2%: Deloitte
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
London
SO FAR this year, the US Food and Drug Administration, gatekeeper to the world's biggest drugs market, has approved 41 novel drugs compared with 22 for the whole of 2016.
It is shaping up to be a bumper year for drug approvals, with US officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Singaporeans can now buy record amount of yen per Singdollar
